ArticleAnnals of dermatology2023
Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment.
Article in Annals of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia-Pacific Modified Delphi Expert Panel Recommendations.International journal of dermatology · 2026Article
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study.Acta dermato-venereologica · 2026Article
- The Clinical Efficacy and Mechanism of Action of Alitretinoin in the Treatment of Alopecia Areata.Annals of dermatology · 2026Article
- Mechanistic study of Erianin in alopecia areata.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 1 country.
Funding
Abstract
backgroundAlopecia areata (AA) is a chronic disease with an unpredictable course and can have a severe psychological impact on an individual.
objectiveTo provide evidence and consensus-based statements regarding the treatment of patients with AA in Korea.
methodsWe searched for relevant studies from inception to May 2021 regarding the systemic treatment of AA. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statement, and an agreement of 75% or greater was considered as having reached consensus.
resultsCurrent evidence supports the efficacy of systemic corticosteroids, oral cyclosporine monotherapy or combination with systemic corticosteroids, and oral Janus kinase inhibitors in severe AA patients. Systemic steroids may be considered for pediatric patients with severe AA. A consensus was achieved in three out of nine (33.3%), and one out of three (33.3%) statements pertaining to systemic treatment in adult and pediatric AA, respectively.
conclusionThe present study produced up-to-date, evidence-based treatment guidelines for AA associated with the consensus obtained by experts based on the Korean healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.